Who Paid My Doc
Giapreza
Drug Emergent Hypotension
NDC 68547-501-02
General payments
$1,583,041
Research payments
$1,005,207
Through program year 2025, $1,583,041 in general payments and $1,005,207 in research payments were reported against Giapreza (Emergent Hypotension).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
11 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $275,084 | 2,121 |
| 2025 | Research | $441,941 | 24 |
| 2024 | General | $256,064 | 1,834 |
| 2024 | Research | $100,920 | 2 |
| 2023 | General | $220,182 | 1,374 |
| 2022 | General | $358,004 | 1,397 |
| 2022 | Research | $8,091 | 2 |
| 2021 | General | $349,981 | 1,020 |
| 2021 | Research | $441,639 | 8 |
| 2020 | General | $123,727 | 822 |
| 2020 | Research | $12,617 | 1 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 72 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 46 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
8,568 general · 37 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.